Increased hypoglycemic effect w/ possible onset of hypoglycemic symptoms or coma w/ miconazole (systemic route, oromucosal gel). Displaced binding to plasma proteins &/or reduced elimination w/ phenylbutazone (systemic route). Inhibited compensatory reactions w/ alcohol. Potentiation of the blood glucose lowering effect w/ other anti-diabetic agents (insulins, acarbose, metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists), β-blockers, fluconazole, ACE inhibitors (captopril, enalapril), H2
-receptor antagonists, MAOIs, sulphonamides, clarithromycin & non-steroidal anti-inflammatory agents. Diabetogenic effect of danazol. Increased blood glucose levels w/ chlorpromazine. Increased blood glucose levels w/ possible ketosis w/ glucocorticoids (intra-articular, cutaneous & rectal prep) & tetracosactrin. Increaed blood glucose levels due to β-2 agonist effects w/ ritodrine, salbutamol, terbutaline. Decreased exposure w/ St. John's wort. Dysglycemia w/ fluoroquinolones. Potentiation of anticoagulant therapy (warfarin).